Combination therapy using active immunotherapy

Abstract

The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof.

1 . A method of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. 
     
     
         2 . The method of  claim 1 , wherein said multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof. 
     
     
         3 . The method of  claim 1  wherein the vaccine comprises the following peptides: SEQ ID NO: 1 (SVASTITGV); SEQ ID NO: 2 (VMAGDIYSV); SEQ ID NO: 3 (ALADGVQKV); SEQ ID NO: 4 (LLGATCMFV); SEQ ID NO: 5 (SVFAGVVGV); SEQ ID NO: 6 (ALFDGDPHL); SEQ ID NO: 7 (YVDPVITSI); SEQ ID NO: 8 (SQDDIKGIQKLYGKRS); SEQ ID NO: 9 (STAPPVHNV); and SEQ ID NO: 10 (LAALPHSCL). 
     
     
         4 . The method of  claim 1  wherein the vaccine comprises at least one peptide selected from the group consisting of SEQ ID NO: 1 (SVASTITGV); SEQ ID NO: 2 (VMAGDIYSV); SEQ ID NO: 3 (ALADGVQKV); SEQ ID NO: 4 (LLGATCMFV); SEQ ID NO: 5 (SVFAGVVGV); SEQ ID NO: 6 (ALFDGDPHL); SEQ ID NO: 7 (YVDPVITSI); SEQ ID NO: 8 (SQDDIKGIQKLYGKRS); SEQ ID NO: 9 (STAPPVHNV); and SEQ ID NO: 10 (LAALPHSCL). 
     
     
         5 . The method of  claim 4  wherein the vaccine comprises SEQ ID NO: 7 (YVDPVITSI); SEQ ID NO: 8 (SQDDIKGIQKLYGKRS) and SEQ ID NO: 9 (STAPPVHNV). 
     
     
         6 . The method of  claim 2  wherein the cancer is renal cancer. 
     
     
         7 . The method of  claim 1 , wherein the method is used as a sole treatment, in an adjuvant, in a neoadjuvant or a palliative therapy setting. 
     
     
         8 . The method of  claim 1 , wherein the vaccine and the multi-kinase inhibitor are administered simultaneously, sequentially or separately. 
     
     
         9 . The method of  claim 1 , wherein the vaccine is administered subcutaneously, intravenously, intradermally, intratumorally, intramuscularly, orally, nasal. 
     
     
         10 . The method of  claim 1 , wherein the multi-kinase inhibitor is administered subcutaneously, intravenously, intradermally, intramuscularly, orally, nasal, 
     
     
         11 . The method of  claim 1 , wherein the routes of administration of the vaccine and the multi-kinase inhibitor are different. 
     
     
         12 . The method of  claim 1 , wherein the routes of administration of the vaccine and the multi-kinase inhibitor are the same. 
     
     
         13 . The method of  claim 1 , wherein the vaccine is administered prior to and/or concurrently with the multi-kinase inhibitor. 
     
     
         14 . The method of  claim 1 , wherein the vaccine is administered concurrently and/or after the multi-kinase inhibitor.